EHA 2023 | The use of ADCs & bispecific antibodies before and after CAR-T therapy in third-line DLBCL
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares insights regarding the treatment of third-line patients with relapsed and refractory diffuse large B-cell lymphoma (R/R DLBCL), focusing on recently approved agents and their potential use in treatment before and after CAR-T therapy, including polatuzumab vedotin, loncastuximab tesirine, and tafasitamab. Dr Strati discusses how real-world data can provide important insights when compared to clinical data and gives an example of how these data compare for treatments using polatuzumab vedotin as a bridging agent prior to CAR-T therapy. Dr Strati then shares further insights on the use of bispecific antibodies after CAR-T therapy. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
PS is a consultant for Roche-Genentech, Kite/Gilead, Hutchison MediPharma, AstraZeneca-Acerta, ADC Therapeutics, Sobi, and TG Therapeutics; he has received research funds from AstraZeneca-Acerta, ALX Oncology, and ADC Therapeutics.
